Clinigen Group Plc (CLIGF) Downgraded by Zacks Investment Research
Clinigen Group Plc (NASDAQ:CLIGF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday.
According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “
Shares of Clinigen Group Plc (CLIGF) traded up 7.34% during trading on Friday, reaching $13.90. 3,637 shares of the company traded hands. The stock has a market cap of $1.60 billion and a PE ratio of 86.34. Clinigen Group Plc has a 52 week low of $8.70 and a 52 week high of $13.90.
TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/08/clinigen-group-plc-cligf-downgraded-by-zacks-investment-research.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clinigen Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group Plc and related companies with MarketBeat.com's FREE daily email newsletter.